ReviewCurrent medical imaging2025
Research Progress of Dual-energy CT in Diagnosis and Evaluation of Curative Effect of Liver Cancer: A Review
Review in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electron Density Dual-energy CT for Liver Metastasis Detection Compared with Conventional and Virtual Monoenergetic Images at 40 keV.Current medical imaging · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer is the sixth most common cancer and the third leading cause of cancer deaths worldwide, with over 900,000 new cases and more than 800,000 deaths annually. Conventional imaging techniques have improved the diagnosis and assessment of treatment response in patients with Hepatocellular Carcinoma (HCC), but they have many limitations. Introducing Dual-Energy Computed Tomography (DECT) into clinical practice offers an opportunity to address these issues. DECT has unique advantages in diagnosing and evaluating the efficacy of HCC treatment. It can provide quantitative information on various substances and, through multi-parameter and quantitative parameter analysis, can be used for early detection of HCC, identification of benign and malignant lesions, and monitoring of lymph node metastasis and Microvascular Invasion (MVI). Additionally, DECT provides valuable information for evaluating therapeutic efficacy. This review covers the imaging principles of DECT, including its basic principles, scanner design modes, and Image Reconstruction (IR) techniques. It then describes the research progress of DECT in diagnosing HCC and evaluating treatment efficacy. Finally, it briefly discusses some limitations of DECT and its future development directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.